The momentum experienced in H2 last year continued into H1, with further strong top line growth in the period YoY. The core pre-clinical market remains supportive and momentum continues to build around the SEND initiative, where Instem has maintained its market leading position. Two acquisitions have now been completed following the £5.0m placing in February, strengthening Instem’s strategic position and adding materially to our growth forecasts. The valuation remains undemanding on an FY17 EV/ ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Instem - Interims again show strong growth
- Published:
19 Sep 2016 -
Author:
Chris Glasper -
Pages:
6
The momentum experienced in H2 last year continued into H1, with further strong top line growth in the period YoY. The core pre-clinical market remains supportive and momentum continues to build around the SEND initiative, where Instem has maintained its market leading position. Two acquisitions have now been completed following the £5.0m placing in February, strengthening Instem’s strategic position and adding materially to our growth forecasts. The valuation remains undemanding on an FY17 EV/ ....